South Korea
· Delayed Price · Currency is KRW ADBiotech Statistics
Total Valuation
ADBiotech has a market cap or net worth of KRW 31.72 billion. The enterprise value is 37.95 billion.
| Market Cap | 31.72B |
| Enterprise Value | 37.95B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ADBiotech has 9.14 million shares outstanding. The number of shares has decreased by -10.35% in one year.
| Shares Outstanding | 9.14M |
| Shares Change (YoY) | -10.35% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 47.07% |
| Owned by Institutions (%) | 5.07% |
| Float | 4.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.22 |
| PB Ratio | 5.63 |
| P/FCF Ratio | 58.36 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.55 |
| EV / Sales | 3.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 69.83 |
Financial Position
The company has a current ratio of 0.58, with a Debt / Equity ratio of 2.44.
| Current Ratio | 0.58 |
| Quick Ratio | 0.36 |
| Debt / Equity | 2.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | 19.82 |
| Interest Coverage | -9.38 |
Financial Efficiency
Return on equity (ROE) is -114.50% and return on invested capital (ROIC) is -12.68%.
| Return on Equity (ROE) | -114.50% |
| Return on Assets (ROA) | -10.33% |
| Return on Capital (ROIC) | -12.68% |
| Revenue Per Employee | 166.51M |
| Profits Per Employee | -141.38M |
| Employee Count | 59 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.46 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +2.30% |
| 50-Day Moving Average | 3,431.10 |
| 200-Day Moving Average | 3,184.28 |
| Relative Strength Index (RSI) | 50.41 |
| Average Volume (20 Days) | 248,558 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ADBiotech had revenue of KRW 9.82 billion and -8.34 billion in losses. Loss per share was -914.52.
| Revenue | 9.82B |
| Gross Profit | 3.60B |
| Operating Income | -4.48B |
| Pretax Income | -11.26B |
| Net Income | -8.34B |
| EBITDA | -3.32B |
| EBIT | -4.48B |
| Loss Per Share | -914.52 |
Balance Sheet
The company has 3.32 billion in cash and 10.77 billion in debt, giving a net cash position of -7.45 billion or -815.14 per share.
| Cash & Cash Equivalents | 3.32B |
| Total Debt | 10.77B |
| Net Cash | -7.45B |
| Net Cash Per Share | -815.14 |
| Equity (Book Value) | 4.42B |
| Book Value Per Share | 616.06 |
| Working Capital | -5.76B |
Cash Flow
In the last 12 months, operating cash flow was 655.96 million and capital expenditures -112.44 million, giving a free cash flow of 543.52 million.
| Operating Cash Flow | 655.96M |
| Capital Expenditures | -112.44M |
| Free Cash Flow | 543.52M |
| FCF Per Share | 59.46 |
Margins
Gross margin is 36.60%, with operating and profit margins of -45.56% and -84.91%.
| Gross Margin | 36.60% |
| Operating Margin | -45.56% |
| Pretax Margin | -114.57% |
| Profit Margin | -84.91% |
| EBITDA Margin | -33.77% |
| EBIT Margin | -45.56% |
| FCF Margin | 5.53% |
Dividends & Yields
ADBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 10.35% |
| Shareholder Yield | 10.35% |
| Earnings Yield | -26.35% |
| FCF Yield | 1.71% |
Stock Splits
The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.
| Last Split Date | May 26, 2021 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
ADBiotech has an Altman Z-Score of -0.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.94 |
| Piotroski F-Score | n/a |